血塞通注射液对慢性乙型肝炎患者肝脏纤维化指标的影响

The Effect of Xuesaitong Injection on Liver Fibrosis Indexes in Patients With Chronic Hepatitis B

目的探讨血塞通注射液对慢性乙型肝炎患者肝脏纤维化指标的影响。方法选取我院2015年9月—2016年11月收治的331例慢性乙型肝炎患者作为研究对象,随机分为研究组(n=139)和对照组(n=192),分别采用血塞通注射液和常规保肝药物治疗,比较分析两组患者治疗前后肝脏瞬时弹性硬度(Fibro Scan)和血清III型前胶原(PCIII)、IV型胶原(IV-C)、层粘连蛋白(LN)、血清透明质酸(HA)水平。结果治疗前,研究组与对照组ALT、T-Bi L、ALB及Fibro Scan、PCIII、IV-C、LN和HA水平对比,差异无统计学意义(P>0.05);治疗后,两组患者PCIII、IV-C和HA水平均较治疗前均降低(P<0.01),但研究组下降程度优于对照组(P<0.01);治疗后,两组Fibro Scan和LN水平与治疗前对比,差异无统计学意义(P>0.05)。结论血塞通注射液可以有效改善慢性乙型肝炎患者部分肝纤维化指标,其远期效果尚有待于进一步研究。

Objective To study the affect on Fibrosis indicator with Xuesaitong injection In patients chronic hepatitis B. Methods 331 cases patients with CHB in our hospital from September 2015 to November 2016, were randomly divided into study group（n=139） with Xuesaitong injection and control group（n=192） with protect liver medicine treatment, compared the Fibro Scan, PCIII, IV-C, LN and HA levels before and after treatment in two groups patients. Results There was no significant difference in the ALT, T-Bi L, ALB and Fibro Scan, PCIII, IV-C, LN, HA levels treatment in two groups patients（P〉0.05）. The PCIII, IV-C and HA levels after treatment in two groups patients were significantly lower than that before treatment（P〈0.01）, and study group decreased more significantly（P〈0.01）. but there was no significant difference in the Fibro Scan and LN levels before and after treatment in two groups（P〉0.05）. Conclusion Xuesaitong injection can improve the fibrosis Indicator in patients with CHB, its long-term effectremains to be further research.